From DCAT Value Chain Insights (VCI)
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization of biologic-based drug substances, has opened its 10,000-square foot, cell-culture process development laboratories in Wilton Center, Teesside, England.
These laboratories were realized through a 1 billion JPY ($9 million) investment, which is part of the greater 14 billion JPY ($130 million) expansion previously announced by Fujifilm Corporation in April 2017. A grant from Let’s Grow, which is part of The Regional Growth Fund, a venture capital firm in England, also contributed to the overall investment as part of Fujifilm Diosynth Biotechnologies’ continued growth in the Tees Valley.
The new laboratories will be dedicated to support the Saturn monoclonal antibody (mAb) Platform cell culture Process Development activities. The Saturn mAb Platform is designed to enable rapid access to process development and manufacturing capacity.
Source: Fujifilm Diosynth Biotechnologies
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription